申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:US10016439B2
公开(公告)日:2018-07-10
The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.
本发明提供了式(I)代表的化合物、其药学上可接受的盐、其N-氧化物、其溶液剂或其原药(其中特征如描述中所定义)。式(I)代表的化合物对γ-氨基丁酸A受体亚基α5(GABAA α5)具有亲和性和选择性,可作为GABAA α5负异位调节剂(GABAA α5 NAM),因此可用于预防和/或治疗与GABAA α5相关的疾病,如阿尔茨海默病。